comparemela.com
7
8
9
10
11
12
13
Latest Breaking News On - Onclive tv - Page 6 : comparemela.com
Dr Nanda on the Evolution of Treatment For HER2-Low Breast Cancer
Rita Nanda, MD, discusses the evolution of treatment options for patients with HER2-low breast cancer.
Rita-nanda
Breast-oncology-program
University-of-chicago
University-of-chicago-medicine-comprehensive-cancer-center
Onclive-tv
Ther2
Dr Olson on the Potential Benefit of Lifileucel in Relapsed/Refractory Metastatic Melanoma
Daniel Olson, MD, discusses the benefit associated with lifileucel in patients with unresectable or metastatic melanoma.
Daniel-olson
University-of-chicago-medical-center
Chicago-medical-center
Melanoma-amp-skin-cancer
Onclive-tv
Dr Narayan on the Mechanism of Action of Nadofaragene Firadenovec in NMIBC
Vikram Narayan, MD, discusses the mechanism of action of nadofaragene firadenovec in patients with high-risk non–muscle invasive bladder cancer.
Vikram-narayan
Department-of-urology
Emory-university-school-of-medicine
Winship-cancer-institute
Urological-oncology
Grady-memorial-hospital
Emory-university-school
Urothelial-cancer
Winship-cancer-institute-of-emory-university
Onclive-tv
Dr Castillo on the Rationale for Evaluating Iopofosine I 131 in Waldenström Macroglobulinemia
Jorge J. Castillo, MD, discusses the rationale for evaluating the iopofosine I 131 in Waldenström macroglobulinemia.
Jorgej-castillo
Dana-farber-cancer-institute
Harvard-medical-school
Bing-center
Onclive-tv
Iopofosinei-131
Waldenström-macroglobulinemia
Clover-wam
Dr Olson on Toxicities Associated With Lifileucel and IL-2 in Melanoma
Daniel Olson, MD, discusses toxicities associated with lifileucel and IL-2 in patients with unresectable or metastatic melanoma.
Daniel-olson
University-of-chicago-medical-center
Chicago-medical-center
University-of-chicago-medicine-comprehensive-cancer-center
Onclive-tv
Melanoma-amp-skin-cancer
vimarsana © 2020. All Rights Reserved.